US EditionCuris to Present at Upcoming Healthcare Conference in April
- James Dentzer, Curis' CEO, will participate in the Jones Healthcare conference on April 9, 2025.
- Curis, a biotechnology firm under the ticker CRIS, focuses on emavusertib development.
- Emavusertib, an IRAK4 inhibitor, is being evaluated in TakeAim lymphoma and leukemia studies.
- Emavusertib received FDA Orphan Drug Designation for PCNSL, AML, and MDS treatment.
- Through a 2015 Aurigene collaboration, Curis has licensed emavusertib and Erivedge to Genentech.
Insights by Ground AI
Does this summary seem wrong?
23 Articles
23 Articles
All
Left
2
Center
6
Right
3
Rutland Herald+22 Reposted by 22 other sources
Curis to Present at Upcoming Healthcare Conference in April
LEXINGTON, Mass., April 2, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that James Dentzer, President and Chief Executive Officer of Curis,…
Coverage Details
Total News Sources23
Leaning Left2Leaning Right3Center6Last UpdatedBias Distribution55% Center
Bias Distribution
- 55% of the sources are Center
55% Center
L 18%
C 55%
R 27%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
